Suche
Mein Konto
ERS Genomics and genOway enter into CRISPR/Cas9 agreement
ERS Genomics and genOway enter into non-exclusive CRISPR/Cas9 agreement to provide access to patent portfolio. Support for preclinical research models.
ERS Genomics and genOway enter into CRISPR/Cas9 agreement
ERS Genomics Limited, established to provide broad access to the fundamental CRISPR/Cas9 intellectual property jointly owned by Dr. Emmanuelle Charpentier and genOway, a leader in the design and development of genetically engineered preclinical research models, today announced a non-exclusive license agreement granting genOway prior and future access to ERS Genomics' CRISPR/Cas9 patent portfolio.
"CRISPR/Cas9 is a powerful in vivo genome engineering tool that has revolutionized many areas of research. At ERS, we are committed to making this technology widely available. We are very pleased to support the development of genOway with this license agreement,"said Eric Rhodes, CEO of ERS Genomics.
“This license from ERS will expand our CRISPR IP portfolio and our offering of rodent models.”said Alexandre Fraichard, CEO of genOway.“This ultimately allows us to pursue our mission of providing the scientific community with highly relevant preclinical models paired with guaranteed freedom of action, especially for commercial applications.”
Financial details of the agreement are not disclosed.
Sources: